Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Neoadjuvant Therapy of Pembrolizumab Combined With Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study

Next Previous
Trial Profile

Efficacy and Safety of Neoadjuvant Therapy of Pembrolizumab Combined With Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Ramucirumab (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms EAST ENERGY

Most Recent Events

  • 06 Jun 2023 Primary endpoint (Major pathologic response (MPR) rate by central review) has been met according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 06 Jun 2023 Results (n=24) assessing the efficacy and feasibility of neoadjuvant therapy with pembrolizumab and ramucirumab in stage IB-IIIA lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 04 Apr 2022 Planned primary completion date changed from 31 Mar 2021 to 30 Apr 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top